SI1964852T1 - Proti-ilt7 protitelo - Google Patents

Proti-ilt7 protitelo

Info

Publication number
SI1964852T1
SI1964852T1 SI200631608T SI200631608T SI1964852T1 SI 1964852 T1 SI1964852 T1 SI 1964852T1 SI 200631608 T SI200631608 T SI 200631608T SI 200631608 T SI200631608 T SI 200631608T SI 1964852 T1 SI1964852 T1 SI 1964852T1
Authority
SI
Slovenia
Prior art keywords
ilt7 antibody
ilt7
antibody
Prior art date
Application number
SI200631608T
Other languages
English (en)
Slovenian (sl)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co. Ltd. filed Critical Sbi Biotech Co. Ltd.
Publication of SI1964852T1 publication Critical patent/SI1964852T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
SI200631608T 2005-12-20 2006-12-20 Proti-ilt7 protitelo SI1964852T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
PCT/JP2006/325391 WO2007072866A1 (ja) 2005-12-20 2006-12-20 抗ｉｌｔ７抗体
EP06842945.5A EP1964852B1 (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Publications (1)

Publication Number Publication Date
SI1964852T1 true SI1964852T1 (sl) 2013-09-30

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200631608T SI1964852T1 (sl) 2005-12-20 2006-12-20 Proti-ilt7 protitelo
SI200632299T SI2913343T1 (sl) 2005-12-20 2006-12-20 Protitelo anti-ILT7
SI200631864T SI2532681T1 (sl) 2005-12-20 2006-12-20 Protitelo proti-ILT7

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200632299T SI2913343T1 (sl) 2005-12-20 2006-12-20 Protitelo anti-ILT7
SI200631864T SI2532681T1 (sl) 2005-12-20 2006-12-20 Protitelo proti-ILT7

Country Status (29)

Country Link
US (6) US8084585B2 (OSRAM)
EP (4) EP2913343B1 (OSRAM)
JP (2) JP5020828B2 (OSRAM)
KR (3) KR101526934B1 (OSRAM)
CN (5) CN120718150A (OSRAM)
AU (1) AU2006328470B2 (OSRAM)
BR (1) BRPI0620141B1 (OSRAM)
CA (2) CA2634116C (OSRAM)
CY (3) CY1114227T1 (OSRAM)
DK (3) DK1964852T3 (OSRAM)
ES (3) ES2526079T3 (OSRAM)
HK (1) HK1218126A1 (OSRAM)
HR (2) HRP20130494T1 (OSRAM)
HU (1) HUE039865T2 (OSRAM)
IL (1) IL192266A (OSRAM)
LT (1) LT2913343T (OSRAM)
ME (1) ME02111B (OSRAM)
MX (1) MX2008007682A (OSRAM)
NZ (3) NZ599683A (OSRAM)
PL (3) PL2913343T3 (OSRAM)
PT (3) PT2532681E (OSRAM)
RS (2) RS52860B (OSRAM)
RU (2) RU2456298C2 (OSRAM)
SG (2) SG10201602095PA (OSRAM)
SI (3) SI1964852T1 (OSRAM)
TR (1) TR201816574T4 (OSRAM)
UA (1) UA97946C2 (OSRAM)
WO (1) WO2007072866A1 (OSRAM)
ZA (1) ZA200805850B (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
EP2563393B1 (en) 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
HUE044838T2 (hu) 2012-03-20 2019-11-28 Biogen Ma Inc JCV neutralizáló antitestek
WO2013142300A2 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
JP6293147B2 (ja) 2012-08-31 2018-03-14 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出のための診断分析およびキット
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
CA2976740A1 (en) * 2015-03-18 2016-09-22 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
LT3313884T (lt) * 2015-06-29 2021-03-10 Immunogen, Inc. Anti-cd123 antikūnai, konjugatai ir jų dariniai
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
BR112018010279A2 (pt) * 2015-11-19 2019-02-05 Abbvie Stemcentrx Llc novos anticorpos anti-emr2 e métodos de uso
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. Automated dental treatment system
WO2017132486A1 (en) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
EP4043492A1 (en) * 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
MX2018010771A (es) * 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
TN2018000341A1 (en) 2016-04-04 2020-06-15 Bioverativ Usa Inc ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
EP3694874A1 (en) 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
CN111712518B (zh) 2017-11-17 2025-03-25 默沙东有限责任公司 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
EP3728301A4 (en) * 2017-12-20 2021-10-06 Radimmune Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST CENTRIN-1, THEIR MANUFACTURING PROCESSES AND THEIR USES
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
CA3099429A1 (en) 2018-05-10 2019-11-14 Cyberdontics (Usa), Inc. Automated dental drill
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
BR112022002579A2 (pt) * 2019-08-12 2022-06-14 Biond Biologics Ltd Anticorpos contra ilt2 e uso dos mesmos
CA3159511A1 (en) * 2019-12-06 2021-06-10 William Rees Methods of treatment using ilt7 binding proteins
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도
EP4208122A4 (en) 2020-09-03 2024-09-11 Perceptive Technologies, Inc. METHOD AND DEVICE FOR CNA ANALYSIS OF DENTAL ANATOMY
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
CN119630703A (zh) 2022-07-27 2025-03-14 维埃拉生物股份有限公司 包含免疫球蛋白样转录物7（ilt7）结合蛋白的配制剂
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
WO2024188356A1 (en) * 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
JP2004500086A (ja) * 2000-02-10 2004-01-08 アボット・ラボラトリーズ ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
PT1446733E (pt) * 2001-10-13 2009-09-28 Asterion Ltd Polipéptidos contendo glicosilfosfatidilinositol
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
CA2537254A1 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
US8470992B2 (en) 2013-06-25
US20170204179A1 (en) 2017-07-20
PT1964852E (pt) 2013-07-10
PL1964852T3 (pl) 2013-09-30
AU2006328470A2 (en) 2008-10-09
CA2994756C (en) 2020-10-27
JPWO2007072866A1 (ja) 2009-06-04
CN110776566B (zh) 2025-07-15
CN105111311B (zh) 2019-10-18
KR20150031485A (ko) 2015-03-24
EP1964852A4 (en) 2010-02-24
CA2994756A1 (en) 2007-06-28
HUE039865T2 (hu) 2019-02-28
DK2913343T3 (en) 2018-11-26
EP2532681A1 (en) 2012-12-12
EP2913343B1 (en) 2018-08-08
US20160130343A1 (en) 2016-05-12
US20200339682A1 (en) 2020-10-29
IL192266A0 (en) 2008-12-29
WO2007072866A1 (ja) 2007-06-28
CN101379089B (zh) 2013-08-07
KR101585532B1 (ko) 2016-01-14
CY1121294T1 (el) 2020-05-29
CN120718150A (zh) 2025-09-30
CN103360492A (zh) 2013-10-23
EP3441403A1 (en) 2019-02-13
EP2532681B1 (en) 2014-10-01
RU2012112046A (ru) 2013-10-10
HK1124347A1 (en) 2009-07-10
US20120135003A1 (en) 2012-05-31
ES2526079T3 (es) 2015-01-05
JP2012143232A (ja) 2012-08-02
HRP20141226T1 (hr) 2015-02-27
HK1214603A1 (en) 2016-07-29
US20090280128A1 (en) 2009-11-12
PL2913343T3 (pl) 2019-03-29
KR101624587B1 (ko) 2016-05-26
CA2634116A1 (en) 2007-06-28
AU2006328470A1 (en) 2007-06-28
CY1116031T1 (el) 2017-01-25
SI2532681T1 (sl) 2015-03-31
KR20140053232A (ko) 2014-05-07
BRPI0620141B1 (pt) 2024-04-30
ME02111B (me) 2015-10-20
RU2599450C2 (ru) 2016-10-10
IL192266A (en) 2014-09-30
AU2006328470B2 (en) 2012-08-16
PT2532681E (pt) 2014-12-23
ES2699428T3 (es) 2019-02-11
LT2913343T (lt) 2018-11-26
CA2634116C (en) 2018-03-27
RU2008129715A (ru) 2010-01-27
SG10201602095PA (en) 2016-05-30
EP1964852A1 (en) 2008-09-03
RU2456298C2 (ru) 2012-07-20
PL2532681T3 (pl) 2015-03-31
SG170749A1 (en) 2011-05-30
NZ616992A (en) 2015-07-31
PT2913343T (pt) 2018-11-21
JP5020828B2 (ja) 2012-09-05
HK1218126A1 (zh) 2017-02-03
SI2913343T1 (sl) 2019-01-31
DK2532681T3 (en) 2015-01-05
KR101526934B1 (ko) 2015-06-26
US8084585B2 (en) 2011-12-27
CN110776566A (zh) 2020-02-11
HK1179638A1 (en) 2013-10-04
BRPI0620141A2 (pt) 2011-11-01
US20130259872A1 (en) 2013-10-03
CN105111311A (zh) 2015-12-02
DK1964852T3 (da) 2013-07-08
RS52860B (sr) 2013-12-31
NZ569910A (en) 2012-06-29
CY1114227T1 (el) 2016-08-31
UA97946C2 (ru) 2012-04-10
ES2416716T3 (es) 2013-08-02
EP2913343A1 (en) 2015-09-02
ZA200805850B (en) 2009-04-29
RS53752B1 (sr) 2015-06-30
TR201816574T4 (tr) 2018-11-21
MX2008007682A (es) 2008-10-23
EP1964852B1 (en) 2013-04-17
CN101379089A (zh) 2009-03-04
HRP20130494T1 (en) 2013-08-31
NZ599683A (en) 2013-11-29
JP5420688B2 (ja) 2014-02-19
KR20080090430A (ko) 2008-10-08

Similar Documents

Publication Publication Date Title
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL192266A0 (en) Anti-ilt7 antibody
IL185366A0 (en) Antibody
SG10201404801YA (en) Monoclonal antibody
IL181575A0 (en) Anti-ox40l antibodies
IL185380A0 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
IL228033A0 (en) Antibodies
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
GB0615662D0 (en) Antibody
GB0420466D0 (en) Anti-glucan antibodies
GB0517487D0 (en) Antibodies
ZA200701952B (en) Anti-OX40L antibodies
IL215527A (en) Methods will notice training
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0505489D0 (en) Antibodies
GB0418415D0 (en) Antibody
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0500400D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies
ZA200709879B (en) Improved immunoassay methods
GB0402641D0 (en) Antibodies